Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olfactory Mucosa-derived MSCs for Covid-19 Pneumonia
NCT04382547Phase 2Completed
- Start
- May 2020
- Primary completion
- Jun 2021
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogenic pooled olfactory mucosa-derived mesenchymal stem cells in COVID-19 pneumonia. Started May 2020; status: completed.
02
Drugs
allogenic pooled olfactory mucosa-derived mesenchymal stem cells
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04382547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04382547.